Timing of Adjuvant Fractionated Stereotactic Radiosurgery Affects Local Control of Resected Brain Metastases.


Journal

Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279

Informations de publication

Date de publication:
Historique:
received: 20 10 2020
revised: 05 01 2021
accepted: 27 01 2021
pubmed: 13 2 2021
medline: 10 8 2021
entrez: 12 2 2021
Statut: ppublish

Résumé

For resected brain metastases (BMs), stereotactic radiosurgery (SRS) is often offered to minimize local recurrence (LR). Although the aim is to deliver SRS within a few weeks of surgery, a variety of socioeconomic, medical, and procedural issues can cause delays. We evaluated the relationship between timing of postoperative SRS and LR. We retrospectively identified a consecutive series of patients with BM managed with resection and SRS or fractionated SRS at our institution from 2012 to 2018. We assessed the correlation of time to SRS and other demographic, disease, and treatment variables with LR, local recurrence-free survival, distant recurrence, distant recurrence-free survival, and overall survival. A total of 133 patients met inclusion criteria. The median age was 64.5 years. Approximately half of patients had a single BM, and median BM size was 2.9 cm. Gross total resection was achieved in 111 patients (83.5%), and more than 90% of patients received fractionated SRS. The median time to SRS was 37.0 days, and the LR rate was 16.4%. Time to SRS was predictive of LR. The median time from surgery to SRS was 34.0 days for patients without LR versus 61.0 days for those with LR (P < .01). The LR rate was 2.3% with SRS administered ≤4 weeks postoperatively, compared with 23.6% if SRS was administered >4 weeks postoperatively (P < .01). Local recurrence-free survival was also improved for patients who underwent SRS at ≤4 weeks (P = .02). Delayed SRS was also predictive of distant recurrence (P = .02) but not overall survival. In this retrospective study, the strongest predictor of LR after postoperative SRS for BM was time to SRS, and a cutoff of 4 weeks was a reliable predictor of recurrence. These findings merit investigation in a prospective, randomized trial.

Identifiants

pubmed: 33578001
pii: S1879-8500(21)00049-7
doi: 10.1016/j.prro.2021.01.011
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e267-e275

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Diana A Roth O'Brien (DA)

Stich Radiation Oncology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

Phillip Poppas (P)

Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

Sydney M Kaye (SM)

Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

Sean S Mahase (SS)

Stich Radiation Oncology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

Anjile An (A)

Division of Biostatistics and Epidemiology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

Paul J Christos (PJ)

Division of Biostatistics and Epidemiology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

Benjamin Liechty (B)

Department of Neuropathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

David Pisapia (D)

Department of Neuropathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

Rohan Ramakrishna (R)

Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

A Gabriella Wernicke (AG)

Savera Liberty Medical, New York, New York.

Jonathan P S Knisely (JPS)

Stich Radiation Oncology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

Susan Pannullo (S)

Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.

Theodore H Schwartz (TH)

Department of Neurosurgery, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York; Department of Otolaryngology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York; Department of Neuroscience, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York. Electronic address: schwarh@med.cornell.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH